N-Phenacylthiazolium bromide (PTB)[1] is a cross-link breaker that in one study has been shown to prevent vascular advanced glycation end-product accumulation in diabetic rats.[2]
Names | |
---|---|
Preferred IUPAC name
3-(2-Oxo-2-phenylethyl)-1,3-thiazol-3-ium bromide | |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
MeSH | C101705 |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C11H10BrNOS | |
Molar mass | 284.17 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
References
edit- ^ Chang, Po-Chun; Tsai, Sheng-Chueh; Chong, Li Yen; Kao, Man-Jung (July 22, 2014). "N-Phenacylthiazolium bromide inhibits the advanced glycation end product (AGE)-AGE receptor axis to modulate experimental periodontitis in rats". Journal of Periodontology. 85 (7): e268–276. doi:10.1902/jop.2014.130554. PMID 24988129.
- ^ Cooper, M. E.; Thallas, V; Forbes, J; Scalbert, E; Sastra, S; Darby, I; Soulis, T (2000). "The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation". Diabetologia. 43 (5): 660–664. doi:10.1007/s001250051355. PMID 10855541.